Glenmark Pharmaceuticals has reported results for third quarter ended December 31, 2021.
The company has reported a rise of 24% in its net profit at Rs 548.52 crore for the quarter under review as compared to Rs 442.33 crore for the same quarter in the previous year. Total income of the company increased by 9.55% at Rs 2249.80 crore for Q3FY22 as compared Rs 2053.61 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported fall of 3.40% in its net profit at Rs 239.75 crore for the quarter under review as compared to Rs 248.18 crore for the same quarter in the previous year. However, total income of the company increased by 13.75% at Rs 3187.31 crore for Q3FY22 as compared Rs 2801.85 crore for the corresponding quarter previous year.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
